Glycocalyx‐Driven Immunomodulation in Trypanosoma cruzi : Structures, Host Responses, Diagnostic and Therapeutic Targeting
Parasite Immunology · 2026-07 · 48 (7)
DOI: 10.1111/pim.70092 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Parasite Immunology, online erschienen am 10.07.2026. Verfasst von Norton Heise und 2 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Hauptthemen laut MEDLINE: Trypanosoma cruzi, Glycocalyx, Chagas Disease, Immunomodulation. Die Arbeit nennt 219 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, NIAID NIH HHS, Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.
Abstract (Originalsprache)
Chagas disease, caused by Trypanosoma cruzi , remains an important neglected infection due to underdiagnosis, global spread resulting from increased migration of people infected with T. cruzi and concomitant organ transplantation and blood transfusion, and limited availability of chemotherapy. The parasite's surface is covered by a dense glycocalyx enriched in GPI‐anchored mucins, trans‐sialidases, and glycoinositolphospholipids (GIPLs), which collectively shape host–parasite interactions. Here we synthesize structural and biosynthetic features of key glycoconjugates and discuss how they modulate innate and adaptive immunity through pattern‐recognition receptors (e.g., TLR2/6 and TLR4), inhibitory lectins (e.g., Siglec‐E), extracellular vesicle signalling, and complement evasion mediated by TS‐like regulators (T‐DAF, TcCRP) and factor H recruitment. We highlight how strain‐ and stage‐specific glycan variation, including α‐Gal p ‐ and β‐Gal f ‐containing epitopes, influences immune recognition, pathogenesis, and persistence. Finally, we evaluate translational opportunities: parasite‐selective targeting of sugar‐nucleotide metabolism and glycosyltransferases, and development of defined glycoepitopes (glycotopes) as improved biomarkers for diagnosis and post‐treatment monitoring. Together, these insights position the T. cruzi glycocalyx as a central driver of immunomodulation and a promising source of therapeutic, vaccine and diagnostic targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
- Instituto Nacional de Ciência e Tecnologia: Glicosaúde, Rio de Janeiro, Brazil.
- Department of Biochemistry & Molecular Biology, Center for Molecular Medicine, Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, Georgia, USA.
ORCID-Profile: Norton Heise, Carolina Macedo Koeller
Förderung
- NIH HHS
- NIAID NIH HHS
- Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
- Instituto Nacional de Ciência e Tecnologia
- National Institutes of Health
Zitieren
APA
Heise, N., West, C. M., & Koeller, C. M. (2026). Glycocalyx‐Driven Immunomodulation in Trypanosoma cruzi : Structures, Host Responses, Diagnostic and Therapeutic Targeting. Parasite Immunology, 48(7). https://doi.org/10.1111/pim.70092
Vancouver
Heise N, West CM, Koeller CM. Glycocalyx‐Driven Immunomodulation in Trypanosoma cruzi : Structures, Host Responses, Diagnostic and Therapeutic Targeting. Parasite Immunology. 2026;48(7). doi:10.1111/pim.70092
BibTeX
@article{Heise2026,
author = {Heise, Norton and West, Christopher Mark and Koeller, Carolina Macedo},
title = {Glycocalyx‐Driven Immunomodulation in Trypanosoma cruzi : Structures, Host Responses, Diagnostic and Therapeutic Targeting},
journal = {Parasite Immunology},
year = {2026},
volume = {48},
number = {7},
doi = {10.1111/pim.70092}
}
EUVIMED